Treatment of recurrent and cystic malignant gliomas by a single intracavity injection of 131i monoclonal antibody: feasibility, pharmacokinetics and dosimetry

Treatment of recurrent and cystic malignant gliomas by a single intracavity injection of 131i monoclonal antibody: feasibility, pharmacokinetics and dosimetry

Play all audios:

Loading...

ABSTRACT A pilot study was undertaken to determine the feasibility of infusing 131I labelled monoclonal antibodies (MoAbs) into either the cavity remaining after resection of malignant glioma or into glioma cysts. Of the seven patients recruited into the study, two had cystic lesions and five resection cavities. Six of the seven were treated after relapse from primary therapy. All patients apart from one, were given a single injection of 131I conjugated to a MoAb (ERIC-1) recognising the human neural cell adhesion molecule (NCAM). One patient received a further injection of 131I-MoAb after regrowth of their disease. Pharmacokinetic studies revealed that the MoAb remained predominantly in the tumour cavity with little leakage into the systemic compartment. This resulted in a high calculated dose of radiation being delivered to the tumour cells either lining or within close proximity to the cavity/cyst wall. In such a small study, it is not possible to determine accurately response rates, but individual patient responses were observed. This, along with the low toxicity noted, demonstrates the feasibility of using 131I-MoAbs in this way. With 131I, radiation dose is deposited in tissue to a depth of 1 mm from the source. The possibility of applying isotopes such as 90Yttrium which will irradiate tumour/tissue to a greater depth (6 mm) is discussed in context with the biology of glioma infiltration into normal brain parenchyma. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 24 print issues and online access $259.00 per year only $10.79 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS SACITUZUMAB GOVITECAN IN PATIENTS WITH BREAST CANCER BRAIN METASTASES AND RECURRENT GLIOBLASTOMA: A PHASE 0 WINDOW-OF-OPPORTUNITY TRIAL Article Open access 07 August 2024 CONVECTION ENHANCED DELIVERY OF RHENIUM (186RE) OBISBEMEDA (186RNL) IN RECURRENT GLIOMA: A MULTICENTER, SINGLE ARM, PHASE 1 CLINICAL TRIAL Article Open access 07 March 2025 NEW APPROACHES TO TARGETED DRUG THERAPY OF INTRACRANIAL TUMORS Article Open access 20 March 2025 AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Imperial Cancer Research Fund, Frenchay Hospital, Bristol, UK V Papanastassiou Authors * V Papanastassiou View author publications You can also search for this author inPubMed Google Scholar * BL Pizer View author publications You can also search for this author inPubMed Google Scholar * HB Coakham View author publications You can also search for this author inPubMed Google Scholar * J Bullimore View author publications You can also search for this author inPubMed Google Scholar * T Zananiri View author publications You can also search for this author inPubMed Google Scholar * JT Kemshead View author publications You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Papanastassiou, V., Pizer, B., Coakham, H. _et al._ Treatment of recurrent and cystic malignant gliomas by a single intracavity injection of 131I monoclonal antibody: feasibility, pharmacokinetics and dosimetry. _Br J Cancer_ 67, 144–151 (1993). https://doi.org/10.1038/bjc.1993.25 Download citation * Issue Date: 01 January 1993 * DOI: https://doi.org/10.1038/bjc.1993.25 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative

ABSTRACT A pilot study was undertaken to determine the feasibility of infusing 131I labelled monoclonal antibodies (MoAbs) into either the cavity remaining after resection of malignant


glioma or into glioma cysts. Of the seven patients recruited into the study, two had cystic lesions and five resection cavities. Six of the seven were treated after relapse from primary


therapy. All patients apart from one, were given a single injection of 131I conjugated to a MoAb (ERIC-1) recognising the human neural cell adhesion molecule (NCAM). One patient received a


further injection of 131I-MoAb after regrowth of their disease. Pharmacokinetic studies revealed that the MoAb remained predominantly in the tumour cavity with little leakage into the


systemic compartment. This resulted in a high calculated dose of radiation being delivered to the tumour cells either lining or within close proximity to the cavity/cyst wall. In such a


small study, it is not possible to determine accurately response rates, but individual patient responses were observed. This, along with the low toxicity noted, demonstrates the feasibility


of using 131I-MoAbs in this way. With 131I, radiation dose is deposited in tissue to a depth of 1 mm from the source. The possibility of applying isotopes such as 90Yttrium which will


irradiate tumour/tissue to a greater depth (6 mm) is discussed in context with the biology of glioma infiltration into normal brain parenchyma. Access through your institution Buy or


subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 24 print issues and online


access $259.00 per year only $10.79 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which


are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS


SACITUZUMAB GOVITECAN IN PATIENTS WITH BREAST CANCER BRAIN METASTASES AND RECURRENT GLIOBLASTOMA: A PHASE 0 WINDOW-OF-OPPORTUNITY TRIAL Article Open access 07 August 2024 CONVECTION


ENHANCED DELIVERY OF RHENIUM (186RE) OBISBEMEDA (186RNL) IN RECURRENT GLIOMA: A MULTICENTER, SINGLE ARM, PHASE 1 CLINICAL TRIAL Article Open access 07 March 2025 NEW APPROACHES TO TARGETED


DRUG THERAPY OF INTRACRANIAL TUMORS Article Open access 20 March 2025 AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Imperial Cancer Research Fund, Frenchay Hospital, Bristol, UK V


Papanastassiou Authors * V Papanastassiou View author publications You can also search for this author inPubMed Google Scholar * BL Pizer View author publications You can also search for


this author inPubMed Google Scholar * HB Coakham View author publications You can also search for this author inPubMed Google Scholar * J Bullimore View author publications You can also


search for this author inPubMed Google Scholar * T Zananiri View author publications You can also search for this author inPubMed Google Scholar * JT Kemshead View author publications You


can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Papanastassiou, V., Pizer, B., Coakham, H. _et


al._ Treatment of recurrent and cystic malignant gliomas by a single intracavity injection of 131I monoclonal antibody: feasibility, pharmacokinetics and dosimetry. _Br J Cancer_ 67, 144–151


(1993). https://doi.org/10.1038/bjc.1993.25 Download citation * Issue Date: 01 January 1993 * DOI: https://doi.org/10.1038/bjc.1993.25 SHARE THIS ARTICLE Anyone you share the following link


with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt


content-sharing initiative